Saksena Devendra, Mishra Yugal K, Muralidharan S, Kanhere Vivek, Srivastava Pankaj, Srivastava C P
Department of Cardiac Surgery, Bombay Hospital, Mumbai, India.
Manipal Hospital, New Delhi, India.
Indian J Thorac Cardiovasc Surg. 2019 Jan;35(Suppl 1):3-44. doi: 10.1007/s12055-019-00789-z. Epub 2019 Jan 28.
Valvular heart disease (VHD) patients after prosthetic valve implantation are at risk of thromboembolic events. Follow-up care of patients with prosthetic valve has a paramount role in reducing the morbidity and mortality. Currently, in India, there is quintessential need to stream line the follow-up care of prosthetic valve patients. This mandates the development of a consensus guideline for the antithrombotic therapy in VHD patients post prosthetic valve implantation.
A national level panel was constituted comprising 13 leading cardio care experts in India who thoroughly reviewed the up to date literature, formulated the recommendations, and developed the consensus document. Later on, extensive discussions were held on this draft and the recommendations in 8 regional meetings involving 79 additional experts from the cardio care in India, to arrive at a consensus. The final consensus document is developed relying on the available evidence and/or majority consensus from all the meetings.
The panel recommended vitamin K antagonist (VKA) therapy with individualized target international normalized ratio (INR) in VHD patients after prosthetic valve implantation. The panel opined that management of prosthetic valve complications should be personalized on the basis of type of complications. In addition, the panel recommends to distinguish individuals with various co-morbidities and attend them appropriately.
Anticoagulant therapy with VKA seems to be an effective option post prosthetic valve implantation in VHD patients. However, the role for non-VKA oral therapy in prosthetic valve patients and the safety and efficacy of novel oral anticoagulants in patients with bioprosthetic valve need to be studied extensively.
人工瓣膜植入术后的心脏瓣膜病(VHD)患者有发生血栓栓塞事件的风险。人工瓣膜患者的随访护理对于降低发病率和死亡率至关重要。目前,在印度,亟需规范人工瓣膜患者的随访护理。这就要求制定一份关于人工瓣膜植入术后VHD患者抗栓治疗的共识指南。
成立了一个国家级专家小组,由印度13位顶尖的心脏护理专家组成,他们全面回顾了最新文献,制定了建议,并编写了共识文件。随后,就该草案和建议在8次区域会议上进行了广泛讨论,另外有来自印度心脏护理领域的79位专家参与,以达成共识。最终的共识文件是依据所有会议的现有证据和/或多数共识制定的。
该专家小组建议,人工瓣膜植入术后的VHD患者采用维生素K拮抗剂(VKA)治疗,并根据个体情况设定国际标准化比值(INR)目标。该专家小组认为,人工瓣膜并发症的管理应根据并发症类型进行个体化。此外,该专家小组建议区分患有各种合并症的个体并给予适当治疗。
VKA抗凝治疗似乎是VHD患者人工瓣膜植入术后的一种有效选择。然而,非VKA口服疗法在人工瓣膜患者中的作用以及新型口服抗凝剂在生物人工瓣膜患者中的安全性和有效性需要进行广泛研究。